Related Experiment Video
Updated: Jul 16, 2026
08:26
Transcriptional Analysis by Nascent RNA FISH of In Vivo Trophoblast Giant Cells or In Vitro Short-term Cultures of Ectoplacental Cone Explants
Published on: August 31, 2016
First epidemiological data from the French Trophoblastic Disease Reference Center
François Golfier1, Daniel Raudrant, Lucien Frappart
1Hospices Civils de Lyon, Hôtel-Dieu, Centre de Référence des Maladies Trophoblastiques, Lyon, France. francois.golfier@chu-lyon.fr
American Journal of Obstetrics and Gynecology
|February 20, 2007
Summary
Gestational trophoblastic neoplasia (GTN) occurred in 14% of complete molar pregnancies and 5% of partial molar pregnancies. Reference centers improve GTN care, with most patients classified as low-risk by FIGO criteria.
Area of Science:
- Gynecology
- Oncology
- Reproductive Endocrinology
Background:
- Gestational trophoblastic neoplasia (GTN) requires specialized management.
- The establishment of French Trophoblastic Disease Reference Centers aims to centralize care and improve outcomes.
- Understanding the incidence of GTN following molar pregnancies is crucial for patient management and resource allocation.
Purpose of the Study:
- To characterize women registered at a new French Trophoblastic Disease Reference Center.
- To determine the incidence rates of gestational trophoblastic neoplasia (GTN) following molar pregnancies.
- To evaluate the risk stratification of GTN patients using the 2000 International Federation of Gynecology and Obstetrics (FIGO) scoring system.
Main Methods:
- Prospective cohort study analyzing epidemiological data.
- Data collected from women registered between November 1999 and November 2004.
- Pathological reclassification of molar pregnancies and GTN risk assessment using the 2000 FIGO scoring system.
Main Results:
- 448 women were registered; 32% of presumed partial moles and 5% of presumed complete moles were reclassified.
- GTN developed in 14% of complete mole and 5% of partial mole cases.
- Of 131 GTN patients, 88% were low-risk and 12% were high-risk according to 2000 FIGO criteria.
Conclusions:
- The creation of specialized trophoblastic disease reference centers is recommended for enhanced patient treatment.
- Findings provide baseline data for future studies comparing outcomes based on the 2000 FIGO oncology committee recommendations.
- Continued monitoring and data collection are essential for refining GTN management protocols.
